Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Pfizer Inc. is conducting a Phase 1b/2 clinical study titled ‘A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer.’ The study aims to evaluate the safety and efficacy of disitamab vedotin in treating advanced breast cancer that is difficult to manage and has spread. This research is significant as it targets patients with HER2-expressing tumors who have undergone previous treatments.
Intervention/Treatment: The study tests disitamab vedotin, a drug administered intravenously every two weeks. It is intended to treat advanced breast cancer by targeting HER2-expressing tumors.
Study Design: This interventional study is non-randomized with a parallel assignment model. It is open-label, meaning there is no masking, and its primary purpose is treatment. Participants are divided into three cohorts based on specific cancer characteristics.
Study Timeline: The study began on June 30, 2025, with primary completion and estimated completion dates yet to be announced. The last update was submitted on July 28, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
Market Implications: This study update could positively influence Pfizer’s stock performance by showcasing its commitment to innovative cancer treatments. Successful outcomes may boost investor confidence and position Pfizer competitively in the oncology market, especially against other companies developing similar therapies.
The study is currently recruiting, with further details available on the ClinicalTrials portal.